Open AccessEstradiol and Progesterone (Bijuva)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.306
Subject(s) - reimbursement , estrogen , progestogen , medicine , drug , menopause , gynecology , vasomotor , endocrinology , pharmacology , political science , health care , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses estrogen-progestogen (Bijuva) in oral capsules, 0.5 mg estradiol (as estradiol hemihydrate)/100 mg progesterone and 1 mg estradiol (as estradiol hemihydrate)/100 mg progesterone.Indication: For the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with an intact uterus.